Close Menu

NEW YORK (GenomeWeb) – Canaccord Genuity today initiated coverage of molecular diagnostics company Natera with a Buy rating. It set a price target of $18.00 for the company's stock.

The San Carlos, California-based company markets a sequencing-based noninvasive prenatal test and is developing cancer products that analyze circulating tumor DNA.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.